title: The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
abstract: Fifteen years ago we discovered activity-dependent neuroprotective protein (ADNP), and showed that it is essential for brain formation/function. Our protein interaction studies identified ADNP as a member of the chromatin remodeling complex, SWI/SNF also associated with alternative splicing of tau and prediction of tauopathy. Recently, we have identified cytoplasmic ADNP interactions with the autophagy regulating microtubule-associated protein 1 light chain 3 (LC3) and with microtubule end-binding (EB) proteins. The ADNP-EB-binding SIP domain is shared with the ADNP snippet drug candidate, NAPVSIPQ termed NAP (davunetide). Thus, we identified a precise target for ADNP/NAP (davunetide) neuroprotection toward improved drug development.
authors.forename: Illana
authors.initials: I
authors.lastname: Gozes
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001321:Autistic Disorder / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D001343:Autophagy / Q000187:drug effects; D003599:Cytoskeleton / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D055808:Drug Discovery; D005786:Gene Expression Regulation / Q000187:drug effects; D018398:Homeodomain Proteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D000066829:Neuroprotection / Q000187:drug effects*; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use; D060066:Protein Interaction Maps / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology
chemical_list: C492178:ADNP protein, human; D018398:Homeodomain Proteins; D009419:Nerve Tissue Proteins; D009842:Oligopeptides; C425904:davunetide